Actimmune as a Potential Treatment Option for Cutaneous T-cell Lymphoma

Student: Jim Lane, 2015-2016

Sponsor: Horizon Pharma, Inc., Chicago, IL

ACTIMMUNE is a man-made biological response marker, interferon gamma-1b, that is integral in regulating the body’s innate and adaptive immune response. The broad influence of interferon gamma on the body’s immune response results in the potential for countless possible therapeutic uses for ACTIMMUNE. ACTIMMUNE has already been studied extensively and is featured in over 250 publications. The goal of the project will be to review these clinical trials to assess their scientific value, regulatory liabilities, and clinical trial design in order to find the most promising areas for additional research. Subsequently, a business case will be generated to support the most propitious research indications. The Horizon team will be integral in deciding which research will be selected for further review, and in the creation of the business case.